metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P- 81 PREVALENCE OF HEV INFECTION IN HIV CARRIERS, PATIENTS WITH INFLAMMATORY BO...
Información de la revista
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Acceso a texto completo
P- 81 PREVALENCE OF HEV INFECTION IN HIV CARRIERS, PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOTIC PATIENTS
Visitas
300
Luan Henrique Paim Santos1, Luíza Araújo de Santana Cavalcanti1, Daniela Santana Mendes1, Victoria Cruz Paraná1, Júlia Stifelman Freire Alves1, Fernanda Souza Novais1, Sidelcina Rugieri Pacheco1, Maria Alice Sant'Anna Zarife3, Hermes Pedreira da Silva Filho4, Carina Carvalho dos Santos2, Ricardo David Couto2, Marina Pamponet Motta2, Carlos Roberto Brites Alves2, Maria Isabel Schinoni2, André Castro Lyra2, Mitermayer Galvão dos Reis1, Luciano Kalabric Silva1
1 Gonçalo Moniz Institute (IGM), Fiocruz, Salvador-BA, Brazil
2 Federal University of Bahia (UFBA), Salvador-BA, Brazil
3 Public Health Central Laboratory of Bahia (LACEN-BA), Salvador-BA, Brazil
4 Recôncavo Federal University of Bahia (UFRB), Cruz das Almas-BA, Brazil
Este artículo ha recibido
Información del artículo
Suplemento especial
Este artículo forma parte de:
Vol. 28. Núm S1

Abstracts of the 2022 Annual Meeting of the ALEH

Más datos
Introduction and Objectives

Hepatitis E is a neglected disease in Brazil. Hepatitis E virus (HEV) can cause chronic illness in immunocompromised patients. This study aimed to determine the seroprevalence and prevalence of HEV infection in different populations: HIV carriers, patients with inflammatory bowel disease (IBD) and cirrhotic patients.

Materials and Methods

The study design was cross-sectional. Participants were recruited from the HIV/AIDS and hepatology outpatient clinic and from the hepatology ward of the University Complex Hospital Professor Edgar Santos (HUPES, UFBA). The proposed sample size was 150 HIV carriers, 100 IBD patients and 50 cirrhotic patients (data and samples collection are in progress). Data were collected through interviews and a review of medical records, and a blood sample was collected for the investigation of anti-HEV IgM and IgG antibodies (Wantai), measurement of serum transaminases AST and ALT (Wiener lab) and detection of HEV -RNA (RealStar® HEV RT-PCR Kit 2.0, Altona).

Results

To date, 214 volunteers have been recruited, 143 of whom have HIV, 38 have IBD and 33 have cirrhosis. Serological tests were performed on a subgroup of 156 samples, 14 of which were reactive for anti-HEV-IgG (Prev. 9.0%; 95% CI: 5.0-14.6%) and none for anti-HEV-IgM (Prev. 0%). In addition, most participants had ALT and AST liver transaminases within the reference range, 88% and 84%, respectively. The seroprevalence of anti-HEV IgG varied according to the group: 14.3% in cirrhotic patients, 8% in IBD patients and 8.5% in HIV patients. The variables with the greatest positive association (PR greater than 2.00) were: being male and eating pork.

Conclusions

Although the data are preliminary, all groups studied were already exposed to HEV. However, no case of current infection was detected. Keywords: hepatitis E, prevalence, HIV, inflammatory bowel disease, cirrhotics. Funding Agencies: Laboratory fee from the Laboratory of Pathology and Molecular Biology (LPBM).

El Texto completo está disponible en PDF
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos